Biocyrst Pharmaceuticals

read moreWe're developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy. We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease. We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE). We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.

read moreOur experienced board supports and upholds the BioCryst commitment to integrity and ingenuity.

read moreBioCryst is constantly seeking to expand and improve its therapeutic development pipeline. It utilizes strategic partnerships early in the drug identification process through in-licensing of drug targets. BioCryst has also established collaborative relationships for the development and commercialization of product candidates to expand its geographic reach beyond the United States. If you are interested in contacting BioCryst regarding partnering opportunities, please email the Business Development team at: businessdevelopment@BioCryst.com.

read moreThis thinking isn't reserved for everything that happens within our walls, but it's how we genuinely feel about the greater medical community. If you have a medical question, please submit your request below. If you have a scientific/medical idea and are seeking support, BioCryst invites you to submit an application for a Medical Educational Grant.